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CLINICO-PATHOLOGIC CHARACTERISTICS AND TREATMENT OUTCOMES
IN CHILDREN WITH NEUROBLASTOMA AT THE KENYATTA NATIONAL
HOSPITAL, Nairobi
G. W. KITONYI, W. M. MACHARIA, O. W. MWANDA and R. PAMNANI
ABSTRACT
Objective: To determine clinical-pathologic characteristics, treatment modalities and
treatment outcomes of children diagnosed with neuroblastoma.
Design: Cross- sectional descriptive study based on secondary data from patient
records.
Setting: Records department of Kenyatta National Hospital (KNH), a tertiary teaching
and referral hospital based in Nairobi.
Subjects: Children aged 15 years and below, admitted with the diagnosis of
neuroblastoma, between January 1997 and December 2005.
Main outcome measures: Presenting clinical features, diagnostic modalities including
laboratory and imaging data, treatment modalities, response to treatment and patient
survival.
Results: Twenty six patients were eligible for the study; 13 males and 13 females
giving a M: F ratio of 1: 1. The age range was 5 days to 12 years, with a median age
of five years. Abdominal swelling (53.8%), inability to walk due to bone pains,
(50%), and cranial or periorbital swelling, (38.5%) were the commonest presenting
features. Diagnosis of neuroblastoma was based on tissue biopsy in 50% (95% CI
40.6-79.8%) of the patients, and on fine needle aspiration cytology of mass or bone
marrow in the rest. Bone marrow involvement was present in 16, (75%). Anaemia,
was common with 72.7% patients having a haemoglobin (HB) <8g/dl at presentation.
Immunohistochemistry and cytological grading were done in two, (8%), patients.
Urinary vanilly l mandelic acid (VMA), screening was positive in 50% (95% CI 29.9%70.1%). The most frequently involved organs were abdomen (88.9%), and skeleton,
(84.6%). Majority of patients, (92.3%), presented with advanced stage IV disease.
Three patients died before commencement of treatment. All treated patients (100%),
received cytotoxic therapy. Only two patients (8.6%) had surgery as part of treatment
while one, (4.3%) was treated with radiotherapy. The initial treatment regimen was
similar for all the patients. Although most patients had a complete initial response to
treatment, early relapse, treatment failure, death or loss to follow up of patients with
progressive disease were common. Overall survival (OS) at one year and two years
were 19.2% (95% CI 6.6-39.4%) and 7.7% (95% CI 0.9%-25 1%) respectively. Only one
patient was alive, (also free of disease), five years after diagnosis.
Conclusion: Although other clinical- pathologic findings of the patients were similar
to those reported elsewhere, virtually all study patients presented with advanced stage
IV disease, which would be associated with poor prognosis irrespective of quality of
care. Priority must therefore be on ensuring early diagnosis and referral of patients
with neuroblastoma before any other interventions can be expected to positively impact
on outcome. The limited role of surgery and radiotherapy observed over the study
period may be attributed to late presentation of the patients. Pathologic evaluation of
patients was inadequate, to some extent due to unavailability of facilities, but extra
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important information could have been availed at minimal extra cost. To be at par with
current internationally accepted treatment approaches that have been associated with
improved survival, there is need to base choice of regimens for individual patients on
clinical and readily accessible pathologic markers.
INTRODUCTION
Neuroblastoma, a malignant childhood embryonal
tumour of the sympathetic neuroblasts is the most
common extra- cranial solid childhood tumour in
the developed world, making up 8% of all malignant
neoplasms in children (1).The tumour arises from sites
where these tissues are distributed and spreads by
contiguous extension, haematogenous or lymphatic
tissues spread. Common metastatic sites are the liver,
bone marrow and skin. Although neuroblastoma is
less common in African children, a significant number
of children are diagnosed with neuroblastoma each
year, leading to considerable morbidity and mortality.
In a study involving 787 cases of childhood cancers at
KNH, (excluding retinoblastoma and brain tumours),
Macharia(2) found a relative neuroblastoma
frequency of 3.3%.
Over half of neuroblastoma patients present
before or at the age of two years. Rarely, neuroblastoma
maybe congenital. Patients commonly present with
abdominal swelling, orbital and periobital masses,
manifesting as proptosis, exophthalmos, and
periorbital oedema. Bone and joint pains, walking
difficulties, and inability to stand, occur due to
skeletal infiltration. Bone marrow involvement is
present in over half of all patients at presentation,
leading to anaemia and occasional thrombocytopenia.
Neurological symptoms may arise from cord
compression or cranial extension of the tumour. A
proportion of patients present with chest tumours,
at times giving rise to superior vena caval syndrome.
Rarely, Horner’s syndrome may be encountered when
there is neck involvement. In neonates subcutaneous
nodules are sometimes present. Non specific clinical
features include irritability, lassitude, weight loss,
fever, vomiting and diarrhoea. Symptoms associated
with catecholamine production and vasoactive
intestinal polypeptide syndrome maybe present in
occasional patients (1).
Ideally all neuroblastoma patients should have
tissue biopsy and histopathology diagnosis, which
should include morphological grading of the tumour
as either high risk, (associated with poor prognosis),
or low risk (3). Neuroblastomas are generally
small round blue cell tumours which sometimes
exhibit pseudorossete formation. In histology
and cytology materials, some neuroblastomas
may be indistinguishable from other small
round blue cell tumours. In these difficult cases
immunohistochemistry (4) and measurement of

catecholamine metabolites vanillymandelic acid
(VMA) or homovanilylmadelic acid (HVMA), are
useful in arriving at a firm diagnosis. VMA and
HVA have been reported as positive in up to 90%
of patients with highly sensitive chromatographic
tests (5). Measurement of VMA is helpful in resource
limited set ups where immunohistochemistry maybe
prohibitively expensive. VMA can also be used for
monitoring therapy. Molecular defects of prognostic
value in neuroblastoma include the MYCN oncogene
over expression, present in about 25% of patients.
Over expression of MYCN overexpression is a
poor prognostic indicator (6). Elevation of serum
ferritin, neurone specific enolase, (NSE), and lactate
dehydrogenase, (LDH), have been associated with
poor prognosis, and would be particularly useful
in centres without facilities to undertake molecular
studies. While LDH and serum ferritin are useful
for disease monitoring response to treatment, NSE
maybe useful in the differentiation of stage IVs from
Stage IV, as the latter is associated with much higher
levels (7).
Disease stage and age at presentation are the most
important predictors of prognosis of neuroblastoma
(l,8). Indeed countries such as Japan, Canada, USA and
United Kingdom have previously carried out VMA
screening programmes in children below the age of
one year, using highly sensitive chromatographic
techniques, with the aim of detecting early, sub clinical
neuroblastoma to improve prognosis. Although the
value and cost effectiveness of these mass screening
programmes remain controversial, this illustrates the
prognostic importance placed on early detection of
neuroblastoma (1). The International Neuroblastoma
Staging System, (INSS), is one of the most widely used
methods of staging neuroblastoma (6). Advanced
disease particularly stage IV is associated with very
poor prognosis while localised stages I, II, has very
favorable prognosis (3).
In the developed world, about 55% of
neuroblastoma patients present with advanced poor
prognosis stage VI disease. Infants aged one year and
below, have a very good prognosis with cure rates
as high as 80% reported, even with advanced Stage
IVS disease (1,8).
Currently patients diagnosed with
neuroblastoma in developed countries are stratified
into three major risk groups; the low risk category,
intermediate risk and a high risk category. Patients
with localized Stages I and II disease, favorable
histology, and without MYCN amplification are
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classified as low risk. Infants below one year
are also included in the low low risk category
including those with Stage VIS disease. Treatment
of this low risk group includes radical surgical
excision of tumour, low intensity chemotherapy
and radiotherapy in some patients (1). Criteria for
high risk assignment include advanced stage IV
disease, presence of MYCN gene amplification and
age above one year. These high risk patients are
treated with high intensity and myelosuppressive
therapy which may necessitate bone marrow rescue
with haemopoietic cell transplants. Intermediate
risk patients may have some features of low risk
and high risk categories, and are treated with
intermediate intensity chemotherapy generally.
Novel therapies include targeted radiotherapy
and immunotherapy. This risk adapted treatment
approach of neuroblastoma which matches clinical
-pathologic features with treatment modality has
yielded very significant improvement in survivals
of neuroblastoma patients in the developed world.
Event free survival of up to 90% has been reported
in the low risk groups. Up to 40 -60% long term
survivals in the intermediate and low risk groups
(6) are being achieved. These superior treatments
outcomes are a result of continuous reviews and
updates of treatments which are carried out every
two years or so. Such frequent reviews maybe
unaffordable in resource limited set ups. However
efforts should nevertheless be made to carry out the
reviews about every five years.
In Kenya, the last review on neuroblastoma
treatment outcomes, but which did not even include
clinical-pathologic features, was carried out by Kasili
et al (9) over 20 years ago. The present study was
carried out to determine both clinical-pathologic
characteristics and treatment outcomes in children
admitted for neuroblastoma treatment at KNH. The
findings of this study may be useful in renewing
attention to presentation and management status of
this childhood malignancy whose local importance is
often overshadowed by the more prevalent childhood
malignancies like lymphomas, nephroblastoma and
leukemia’s.
MATERIALS AND METHODS
Study design, setting and subjects: This was a crosssectional descriptive study based on review of
patients’ records. The study period was January 1997
to December 2005. Records of all children aged 15
years and below, with the diagnosis of neuroblastoma,
were retrieved and data extracted using pre-designed
data extraction sheets.
Case definition: Only subjects with a histopathology
or cytology, (tumour, bone marrow or both),
diagnosis consistent with neuroblastoma were
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eligible for inclusion. Cases with clinical features of
neuroblastoma, but doubtful histology or cytology,
were included if the urinary VMA was positive.
Data collection: All records of eligible patients were
retrieved and scrutinised. Information on age at
presentation, sex, presenting complaint(s) and
duration, which included presence of swelling and
their sites, pain and inability to walk, evidence
of neurological disease, non specific signs and
symptoms, (such as weakness, fever, diarrhoea,
vomiting, irritability, and excessive sweating) were
captured and recorded in pre-designed data extraction
sheets. Laboratory data including full blood counts,
clinical chemistry, (liver function and kidney function
tests, LDH, ferritin, uric acid and urinary VMA
screening results, histopathology reports, FNA and
bone marrow cytology reports were also recorded.
Diagnostic imaging results, (chest X-rays, skeletal
surveys, abdominal ultrasound, CT scans and MRI
reports), were also recorded. Staging of disease
was noted and recorded, and where not indicated
retrospective staging done according to the INSS.
Treatment and treatment modalities were included.
For patients who had surgery, the type and reason
for surgery was also extracted. Where chemotherapy
was given, the protocol, number of courses given
and completed was recorded. Response to treatment
was classified as complete, partial, minor or none.
Patients who got radiotherapy and their response
to radiotherapy were noted. Survival was measured
from the time the patient was first seen at KNH, to the
last time they were seen alive with or without disease.
Where patients were lost to follow up with progressive
disease, or transferred to the nearest hospital with
unresponsive disease, this was also noted.
Data analysis: The data was computerised cleaned and
verified using the SPSS version 10.0 software. Analysis
was basically frequency analysis, giving rise to median
and descriptive proportions. Baseline characteristics
were tabulated and frequency of variables calculated.
Ninety five per cent Confidence intervals were
calculated for primary outcome measures to indicate
accuracy of the estimates. P-values of less than 0.05
were considered as significant. Overall survival was
calculated from the date of admission to the date of last
follow up when status, (dead or alive) with presence
or absence of malignant disease also noted.
RESULTS
Although 57 patient’s files had a diagnosis of
neuroblastoma, 31 cases were excluded from
analysis because either the diagnosis was equivocal
or the records were incomplete, leaving 26 cases.
Age range was 5 days to 12 years, the median age
five years. As shown in Table 1, 50% of the patients
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were aged two years and below. Male: Female
ratio was 1:1, with 13 males and 13 females. Table
2 summarises the presenting features and shows
that the commonest presenting features were
abdominal swelling 14, (53.8%), inability to walk
due to bone pains,13, (50%), and head or orbital
swellings, 10, (38.5%). Over half of the patients had
non specific symptoms, such as, fever, vomiting,
irritability, diarhoea and fatigue. Based on clinical,
laboratory and diagnostic imaging, the abdomen
(88.9%); skeleton (84.6%), bone marrow (75%)
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and the head and neck (36.8%) were the most
frequently involved sites as seen in Figure 1. In
Table 3 it is noted that most patients, 24, (92.3%)
presented with advanced stage IV disease. Table
4 shows laboratory characteristics at presentation.
Anaemia was common with 16, (72.7%) patients
having an Hb equal to or less than 8g/dl. Bone
marrow involvement was present in 12 out of 16
(75%) patients examined. One patient presented
with an isolated testicular mass, whose diagnosis
was confirmed with immunohistochemistry.

Table 1
Distribution of neuroblastoma patients at presentation by age and gender (n=22)
Age (years)
> 1
1 - 2
3 - 6
7 - 10
11-15
Total

Male
4
3
0
1
3
11

Female
3
1
3
3
1
11

Total
7
4
3
4
4
22

(%)
31.8
18.2
13.6
18.2
18.2
100

Cumulative (%)
31.8
50
63.6
81.5
100

NB: The age was not clearly indicated in the records of four patients
Table 2
Presenting clinical features in 26 children with neuroblastoma
Clinical feature
Abdominal swelling
Inability to walk and bone pains
Swellings on the head and proptosis
Fever
Weakness
Vomiting
Sweating
Swellings elsewhere (testis and femur)
Others (one each)*

No. of patients
14
13
10
5
4
3
2
2
3

*Diarrhoea, convulsions and superior vena caval syndrome
Note: Some patients had more than one presenting symptoms

(%) of total
53.8
50
38.5
19.8
15.4
11.5
7.7
7.7
11.5
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Table 3
Disease stage at presentation in 26 children with neuroblastoma according to the International Neuroblastoma
Staging System
Stage
I

No. of patients
0

% of patients
0

IIA

0

0

IIB

1

3.8

III

0

0

IV

24

92.3

IVS

1

3.8

Staging criteria
Localised tumour with complete gross excision,
with or without microscopic residual disease:
representative ipsilateral lymph nodes negative for
tumour microscopically, (nodes attached to and
removed with the tumour maybe positive)
Localised tumour with or without complete gross
excision with ipsilateral non-adherent lymph nodes
negative for tumour. Enlarged contra-lateral lymph
nodes must be negative tumour microscopically
Localised tumour with or without complete excision,
with ipsilateral nonadherent lymph nodes positive
for tumour. Enlarged Contra- lateral lymph nodes
must be negative microscopically
Unresectable unilateral tumour infiltrating across
the midline, with or without regional lymph node
involvement; or localised unilateral tumour with
contra- lateral regional lymph node involvement: or
midline tumour with bilateral extension by infiltration
(unresectable) or by lymph node involvement
Any primary tumour with dissemination to distant
lymph nodes, bone, bone marrow, liver, skin or
other organs (except Stage 4S*)
Localised primary tumour as defined for stages 1, 2A
or 2B, with dissemination limited to skin, liver, and
or bone marrow involvement (10% involvement)

Table 4
Laboratory characteristics of children with neuroblastoma before commencement of treatment
Characteristic
Hb* level (g/dl)
8.0 - 5.0
Bone marrow cytology done
Bone marrow involvement among those
Who had bone marrow aspiration
FNA-C** of tumour done
Positive for neuroblastoma
Tissue biopsy for diagnosis (n= 16)
Number who had histological grading
Number who had immunohistochemistry
Urinary screening for VMA ***
Number with positive VMA
Number whose LDH level was tested
Number with elevated LDH
* Hb = Haemoglobin. The lowest Hb was 5.4g/dl
**FNAC = Fine needle aspirate cytology
***VMA = Vanilyl mandelic acid

No.

(%)

16
16
12

72.7
72.7
75.0

18
16
8
2
2
12
6
3
3

81.8
72.7
50
12.5
12.5
54.5
50.0 (of those tested)
13.6
100 (of those tested)
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Figure 1
Frequency of involvement of various body sites at presentation
Abdomen
Skeleton
Bone marrow
Head and Neck
Nervous system
Intrathoracic
Testis
0

20

40

60

80

100

% of involved sites

Table 5
Results of imaging in children with neuroblastoma, ( before treatment)
Mode of imaging

Number with
(%)
abnormal findings
		
CXR (n=12)
10
83
			
			
			
Abdominal (n=14)
ultrasound
13
92.9
			
			
Skeletal X-rays (n=8)
(excluding chest)
8
100
			
			

Type of abnormality

Pneumonic changes, (n=4)
Mediastinal masses (n=3)
Lytic lesions (n=2)
Pleural effusion (n=1)
Complex and other abdominal masses and
enlarged para-aortic nodes (n=7)
Suprarenal masses (n=4)
Liver metatasis (n=3)
Lytic lesions (n=8)
Expanding masses (n=2)
Sutural diastasis (n=1)

IVUs (3)
3
100
			

Suprarenal mass (n=2)
Retroperitoneal mass (n=1)

CT Scans
4
100
			
			
			

Destructive orbital mass (n=1)
Intracranial tumour (n=1)
Thoracis mass (n=1)
Liver metastasis (n=1)

NB: Some patients had more than one type of imaging, while some had multiple lesions
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Urinary VMA screening using visual colour change
method, was positive in 50% (CI 29.9- 70.1 %), of
the patients who were screened. LDH was elevated
in all the four patients for whom it was done,
(at diagnosis) and results were available. None
of the patients had serum ferritin or NSE levels
estimated. Liver transaminases were elevated in
two patients, one of whom had a positive hepatitis
B surface antigen. Renal functions were normal
in all patients. Histopathology was the basis for
diagnosis in 50% (CI 40.6-79.80%) patients’ records
available, while the rest had a diagnosis based on
FNA of tumour or bone marrow cytology together
with VMA findings. Two patients, (8%), who had
difficult histology, had confirmation of diagnosis by
immunohistochemistry done in a foreign country.
These two histologies also had histological grading
indicated on the reports carried out overseas.
Amongst the 12 patients who had FNA cytology, two
also had tissue biopsy and in these cases cytology
and histopathology results concurred. Table 5
summarises the types and results of the patient’s
imaging. Abnormal imaging results were present
in majority of the patients.
Table 6
Treatment outcome and survival of neuroblastoma
patients
Response to treatment (n=19*)

No. (%)

Complete initial response,
(>90% decrease in tumour size)

7

42.1

Partial response

5

26.3

6

31.6

19

100

Died within 6 months**

16

61.5

Survived up to 1 year

5

19.2

Survived up to 2 years

2

7.7

Survived up to 5 years

1

3.8

(50-90% decrease in tumour size)
Minor or no response
(>25% reduction in tumour size)
Total
Survival of 26 neuroblastoma patients
with or without treatment

* Three patients died before commencement of
treatment
** Includes two patients lost to follow up with
progressive terminal disease, presumed dead

Table 6 shows treatment response and survival
of the patients. Three very ill patients died before
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treatment commencement. The rest of the patients
all (100%) underwent combination chemotherapy
with vincristine, cyclosphosfamide, adriamycin
and cis- platin by either one of 2 protocols (10, 11).
Radiotherapy was given to only one patient who
had a complex pelvic mass compressing the ureters
and causing hydronephrosis, a hydrocoele and
renal failure. The tumour responded favorably to
radiotherapy initially with partial regression of the
tumour. However recurrence at the same site within
a few weeks, led to death of the patient from renal
failure.
Majority of the patients had initial complete or
partial response to chemotherapy. However most had
subsequent relapse and resistance to chemotherapy
and either died or were discharged with progressive
disease. Overall survival at one and two years was
19.2% (CI 6.6- 39.4%) and 7.7% (CI 0.925 - 25.1%)
respectively. Only one patient, (3.8%), who had
presented with stage 2B disease, survived, (also
disease free) beyond five years (3.8%).
DISCUSSION
The clinical presentation of patients in this study are
very similar to what has been described elsewhere
in both developed and developing countries (3, 6,
12). The youngest patient presented at KNH with
anaemia and abdominal distension at the age of five
days. According to the history, abdominal masses and
anaemia were noted soon after birth. Most probably
this patient had congenital neuroblastoma. Half of
the patients were aged two years and below. The
commonest presenting features included swellings
of the abdomen, inability to walk due to bone pains
and non specific symptoms such as weakness, fever,
vomiting and sweating. The most frequently involved
sites were the abdomen, skeleton, head and neck. Bone
marrow involvement and anaemia were frequent.
These findings are comparable with what is reported
in the literature (1,3,13).
However majority presented with advanced
stage IV disease. One unusual case was a patient
who presented with an isolated testicular swelling, a
rare finding in neuroblastoma (1). Despite complete
excision of the tumour, followed by chemotherapy and
radiotherapy, there was aggressive tumour regrowth
with compression of the ureters, renal failure and
death of the patient.
Ideally all patients with neuroblastoma should
have a tissue diagnosis in which the risk category
is indicated to guide in the decision of appropriate
intensity of treatment (1). Half of the patients whose
data was available did not have tissue diagnosis. To
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improve our treatment outcomes of neuroblastoma, it
will be necessary to ensure that all patients suspected
to have neuroblastoma have tissue biopsy, not only
to improve the accuracy of diagnosis, but to also help
with risk categorisation and possible risk adaptation
of the treatment.
Only half of patients whose records could be
evaluated had VMA screening. Expensive techniques
like immunohistochemistry may not be affordable in
public hospitals in Kenya but it is recommended that
more affordable tests like a sensitive VMA test and
serum ferritin be made readily available to improve
on the diagnosis of neuroblastoma in resource
constrained set ups.
Although surgery and radiotherapy have
important roles in treatment of neuroblastoma
(12), only one patient had surgery as a debulking
procedure in this study. This patient had the best
prognosis. Radiotherapy was given to only one patient
as a palliative measure. The limited role of surgery
and radiotherapy is most likely related to the late
presentation of the patients in this study.
Over 20 years back, Kasili et al (9) noted that
neuroblastoma had the poorest prognosis of all
paediatric solid tumours managed at the KNH. He also
noted that this was associated with late presentation
of patients. The prognosis of neuroblastoma remains
very poor compared to the greatly improved results
recorded by developed countries (1, 3, 9). As long as
patients continue to present with advanced disease,
the prognosis of neuroblastoma is likely to remain
poor irrespective of the quality of care or any other
interventions.
A significant limitation of this study was the small
number of subjects that met eligibility criteria because
of missing data. This is however not surprising with
a retrospective study. A prospective study is therefore
recommended which should avail more precise
information.
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